Upgrade to SI Premium - Free Trial

Stifel on SpyGlass Pharma (SGP): complete enrollment indication reinforces approval confidence

March 27, 2026 12:26 PM
Stifel analyst Tom Stephan reiterated a Buy rating and $42.00 price target on SpyGlass Pharma (NASDAQ: SGP)The analyst commented, "Alongside ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments